Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 125, Issue 7, 2017, Pages 419-435

  Leiter, Lawrence A ^a   Nauck, Michael A ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

glucagon like peptide 1; hyperglycaemia; hypoglycaemic agents; incretins; type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGONISTS; BLOOD; PHASE 3 CLINICAL TRIAL (TOPIC);

CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 85025113297     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0043-103969     Document Type: Article

References (106)

1. Kahn S. E. Haffner S. M. Heise M. A. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med: 2006; 355 2427 2443
2. American Diabetes Association. Standards of medical care in diabetes - 2016. Diabetes Care 2016; 39 (Suppl 1): Available at http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement-1.DC2/2016-Standards-of-Care.pdf
3. ESC/EASD Task Force on Diabetes ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J: 2013; 34 3035 3087 Available at https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/eht108
4. Matthaei S. Bierwirth R. Fritsche A. et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: Update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes: 2009; 117 522 557
5. Nauck M. A. Meier J. J. The incretin effect in healthy individuals and those with type 2 diabetes: Physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol: 2016; 4 525 536
6. Nauck M. A. Kleine N. Orskov C. et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia: 1993; 36 741 744
7. Seufert J. Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: A focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab: 2014; 16 673 688
8. Inzucchi S. E. Bergenstal R. M. Buse J. B. et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care: 2012; 35 1364 1379
9. Meier J. J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol: 2012; 8 728 742
10. Unger J. R. Parkin C. G. Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications. Diabetes Ther: 2011; 2 29 39
11. Lorenz M. Pfeiffer C. Steinsträsser A. et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - relationship to postprandial glycemia. Regul Pept: 2013; 185 1 8
12. Diamant M. Nauck M. A. Shaginian R. et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care: 2014; 37 2763 2773
13. Yu Pan C. Han P. Liu X. et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: A randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev: 2014; 30 726 735
14. Bhavsar S. Mudaliar S. Cherrington A. Evolution of exenatide as a diabetes therapeutic. Curr Diabetes Rev: 2013; 9 161 193
15. Eng J. Kleinman W. A. Singh L. et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem: 1992; 267 7402 7405
16. DeFronzo R. A. Okerson T. Viswanathan P. et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study. Curr Med Res Opin: 2008; 24 2943 2952
17. Kastin A. J. Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord: 2003; 27 313 318
18. Göke R. Larsen P. J. Mikkelsen J. D. et al. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci: 1995; 7 2294 2300
19. Fehse F. Trautmann M. Holst J. J. et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab: 2005; 90 5991 5997
20. Kolterman O. G. Buse J. B. Fineman M. S. et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab: 2003; 88 3082 3089
21. Diamant M. Van Gaal L. Stranks S. et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet: 2010; 375 2234 2243
22. Lyxumia [Summary of Product Characteristics]. Paris, France Sanofi-Aventis Groupe: 2013
23. Hunter K. Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci: 2012; 13 33
24. Barnett A. H. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid: 2011; 6 67 79
25. Rosenstock J. Hanefeld M. Shamanna P. et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complications: 2014; 28 386 392
26. Victoza [Summary of Product Characteristics]. Bagsvaerd, Denmark Novo Nordisk: 2013
27. Neumiller J. J. Sonnett T. E. Wood L. D. et al. Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes Metab Syndr Obes: 2010; 3 215 226
28. Pratley R. E. Nauck M. A. Barnett A. H. et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol: 2014; 2 289 297
29. Degn K. B. Juhl C. B. Sturis J. et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24- h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes: 2004; 53 1187 1194
30. Saxenda [package insert]. Plainsboro, NJ Novo Nordisk, Inc: 2015
31. Bydureon [Summary of Product Characteristics]. Södertälje, Sweden AstraZeneca AB: 2015
32. Drucker D. J. Buse J. B. Taylor K. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet: 2008; 372 1240 1250
33. Trulicity [Summary of Product Characteristics]. Houten, The Netherlands Eli Lilly Nederland B.V.: 2014
34. Gupta V. Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab: 2013; 17 413 421
35. Barrington P. Chien J. Y. Showalter H. D. et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab: 2011; 13 426 433
36. Trulicity [package insert]. Indianapolis, IN Eli Lilly and Company: 2014
37. Umpierrez G. Tofé Povedano S. Pérez Manghi F. et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care: 2014; 37 2168 2176
38. Eperzan [Summary of Product Characteristics]. County Cork, Ireland GlaxoSmithKline Trading Services Limited: 2014
39. Tanzeum [package insert]. Research Triangle Park, NC GlaxoSmithKline: 2016
40. Rosenstock J. Matthews M. W. Albiglutide. Glucagon-like peptide GLP-1 receptor agonist. Treatment of type 2 diabetes. Drugs Fut: 2010; 35 701 712
41. Matthews J. E. Stewart M. W. De Boever E. H. et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab: 2008; 93 4810 4817
42. Hottenstein CS, Szapacs ME, Maier CC. Investigation of blood-brain barrier penetration of albiglutide in mice [abstract 788]. Diabetes 2016; 65 (Suppl 1): Available at http://app.core-apps.com/tristar-ada16/abstract/92b0eac0f984437a5bebc08c57516262
43. Leiter L. A. Mallory J. M. Wilson T. H. et al. Gastrointestinal safety across the albiglutide development programme. Diabetes Obes Metab: 2016; 18 930 935
44. Lau J. Bloch P. Schaffer L. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem: 2015; 58 7370 7380
45. Sorli C, Harashima SI, Tsoukas GM et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 2017
46. Moretto T. J. Milton D. R. Ridge T. D. et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther: 2008; 30 1448 1460
47. Fonseca V. A. Alvarado-Ruiz R. Raccah D. et al. EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care: 2012; 35 1225 1231
48. Garber A. Henry R. Ratner R. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet: 2009; 373 473 481
49. Russell-Jones D. Cuddihy R. M. Hanefeld M. et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study. Diabetes Care: 2012; 35 252 258
50. Nauck M. Stewart M. Perkins C. et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia: 2016; 59 266 274
51. Garber A. J. Abrahamson M. J. Barzilay J. I. et al. AACE comprehensive diabetes management algorithm. 2013; Endocr Pract: 2013; 19 327 336
52. DeFronzo R. A. Ratner R. E. Han J. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care: 2005; 28 1092 1100
53. Ahrén B. Leguizamo Dimas A. Miossec P. et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care: 2013; 36 2543 2550
54. Bolli G. B. Munteanu M. Dotsenko S. et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med: 2014; 31 176 184
55. Nauck M. Frid A. Hermansen K. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The lead (liraglutide effect and action in diabetes)-2 study. Diabetes Care: 2009; 32 84 90
56. Bergenstal R. M. Wysham C. Macconell L. et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet: 2010; 376 431 439
57. Nauck M. Weinstock R. S. Umpierrez G. E. et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care: 2014; 37 2149 2158
58. Ahrén B. Johnson S. L. Stewart M. et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care: 2014; 37 2141 2148
59. Kendall D. M. Riddle M. C. Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care: 2005; 28 1083 1091
60. Zinman B. Hoogwerf B. J. Durán Garcia S. et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med: 2007; 146 477 485
61. Pinget M. Goldenberg R. Niemoeller E. et al. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab: 2013; 15 1000 1007
62. Zinman B. Gerich J. Buse J. B. et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care: 2009; 32 1224 1230
63. Reusch J. Stewart M. W. Perkins C. M. et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab: 2014; 16 1257 1264
64. Home P. D. Shamanna P. Stewart M. et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab: 2015; 17 179 187
65. Ahrén B, Comas LM, Kumar H et al. Efficacy and safety of once-weekly semaglutide vs. sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2). Abstract number 185-OR. American Diabetes Association 76th Scientific Session, New Orleans, US; 10-14 June 2016. Available at: http://app.core-apps.com/tristar-ada16/abstract/92b0eac0f984437a5bebc08c57aceb8b
66. Rosenstock J. Raccah D. Korányi L. et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care: 2013; 36 2945 2951
67. Buse J. B. Rosenstock J. Sesti G. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet: 2009; 374 39 47
68. Blevins T. Pullman J. Malloy J. et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab: 2011; 96 1301 1310
69. Wysham C. Blevins T. Arakaki R. et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care: 2014; 37 2159 2167
70. Buse J. B. Nauck M. Forst T. et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study. Lancet: 2013; 381 117 124
71. Dungan K. M. Povedano S. T. Forst T. et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial. Lancet: 2014; 384 1349 1357
72. Ahmann A, Capehorn M, Charpentier G et al. Efficacy and safety of once-weekly semaglutide vs. exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3). Abstract number 187-OR. American Diabetes Association 76th Scientific Session, New Orleans, US; 10-14 June 2016. Available at: http://app.core-apps.com/tristar-ada16/abstract/92b0eac0f984437a5bebc08c57acdd6f
73. Heine R. J. Van Gaal L. F. Johns D. et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med: 2005; 143 559 569
74. Russell-Jones D. Vaag A. Schmitz O. et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia: 2009; 52 2046 2055
75. Blonde L. Jendle J. Gross J. et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet: 2015; 385 2057 2066
76. Weissman P. N. Carr M. C. Ye J. et al. HARMONY 4: Randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia: 2014; 57 2475 2484
77. Aroda V, Bain S, Cariou B et al. Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4). Abstract 290. American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress 2016. Orlando, FL. Available at: http://journals.aace.com/doi/pdf/10.4158/1530-891X-22.s2.29
78. Abd El Aziz M. S. Kahle M. Meier J. J. et al. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab: 2016; [e-pub before print] 10.1111/dom.12804
79. Riddle M. C. Aronson R. Home P. et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care: 2013; 36 2489 2496
80. Riddle M. C. Forst T. Aronson R. et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care: 2013; 36 2497 2503
81. Mathieu C. Rodbard H. W. Cariou B. et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab: 2014; 16 636 644
82. Ahmann A, Rodbard HW, Rosenstock J et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2015; 17: 1056-1064
83. Pozzilli P, Norwood P, Jobar E et al. Improved glycemic control and weight loss with once-weekly dulaglutide vs. placebo, both added to titrated daily insulin glargine, in type 2 diabetes patients (AWARD-9) [abstract]. Diabetes 2016; 65 (Suppl 1): Available at http://app.core-apps.com/tristar-ada16/abstract/92b0eac0f984437a5bebc08c57b9d8b1 Accessed 6 December 2016
84. Rosenstock J. Fonseca V. A. Gross J. L. et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: A comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care: 2014; 37 2317 2325
85. Rodbard H, Lingvay I, Reed J et al. Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5). Abstract 766. European Association for the Study of Diabetes 52nd Annual Meeting 2016. Munich, Germany. Available at: http://www.easdvirtualmeeting.org/resources/efficacy-and-safety-ofsemaglutide-once-weekly-vs-placebo-as-add-on-to-basal-insulinalone-or-in-combination-with-metformin-in-subjects-with-type-2-diabetes-sustain-5
86. Giorda C. B. Nada E. Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine: 2014; 46 406 419
87. Leiter L. A. Carr M. C. Stewart M. et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: A randomized phase III study. Diabetes Care: 2014; 37 2723 2730
88. Davies M. J. Bain S. C. Atkin S. L. et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial. Diabetes Care: 2016; 39 222 230
89. Victoza [package insert]. Plainsboro, NJ Novo Nordisk Inc: 2016
90. Drucker D. J. Nauck M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet: 2006; 368 1696 1705
91. Frías J. P. Guja C. Hardy E. et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol: 2016; 4 1004 1016
92. Byetta [Summary of Product Characteristics]. Södertälje, Sweden AstraZeneca AB: 2016
93. Bydureon [package insert]. Wilmington, DE AstraZeneca Pharmaceuticals LP: 2015
94. Byetta [package insert]. Wilmington, DE AstraZeneca Pharmaceuticals LP: 2015
95. Egan A. G. Blind E. Dunder K. et al. Pancreatic safety of incretin-based drugs - FDA and EMA assessment. N Engl J Med: 2014; 370 794 797
96. Pfeffer M. A. Claggett B. Diaz R. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med: 2015; 373 2247 2257
97. Marso S. P. Daniels G. H. Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med: 2016; 375 311 322
98. Marso S. P. Bain S. C. Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med: 2016; 375 1834 1844
99. Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes. 2016; Available at: www.intarcia.com/media/pressreleases/2016-may-6-cardiovascular-safety.html Accessed 3 August, 2016
100. ClinicalTrials.gov. NCT01144338 Exenatide study of cardiovascular event lowering trial (EXSCEL): A trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. 2016; Available at: https://clinicaltrials.gov/ct2/show/NCT01144338 Accessed 8 June, 2016
101. ClinicalTrials.gov. NCT01394952 Researching cardiovascular events with a weekly incretin in diabetes (REWIND). 2016; Available at: https://clinicaltrials.gov/ct2/show/NCT01394952 Accessed 8 June, 2016
102. ClinicalTrials.gov. NCT02465515 Effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in subjects with type 2 diabetes mellitus. 2016; Available at: https://clinicaltrials.gov/ct2/show/NCT02465515 Accessed 8 June, 2016
103. Petersen A. B. Christensen M. Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndr Obes: 2013; 6 217 231
104. Xultophy [Summary of Product Characteristics]. Bagsvaerd, Denmark Novo Nordisk A/S: 2016
105. Charbonnel B. Bertolini M. Tinahones F. J. et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: A meta-analysis. J Diabetes Complications: 2014; 28 880 886
106. Monami M. Dicembrini I. Marchionni N. et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: A meta-analysis. Exp Diabetes Res: 2012; 2012 672658